Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01472419

Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma

Metastatic Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:
Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients

Clinical Trial Summary

Esophageal squamous cell carcinoma is considerably more prevalent in East Asia. Despite of relatively high prevalence of esophageal SCC, prognosis is very poor with limited options of effective chemotherapy regimens. We attempted to identify favorable subgroups of patient who are likely to benefit from 5- fluorouracil/cisplatin(FP) or capecitabine/cisplatin (XP) chemotherapy as first-line treatment.Between January 2000 to December 2010, 239 patients were diagnosed of recurrent, metastatic esophageal SCC and received either FP or XP as first-line chemotherapy. Clinicopathologic variables and treatment outcome were retrospectively collected. we analysis treatment outcome of palliative chemotherapy in metastatic esophageal squamous cell carcinoma and make prognostic scoring system. The present study represents the largest series to analyze the treatment outcome of FP/XP chemotherapy in metastatic SCC. Risk-adapted stratification of treatment for subgroup of metastatic SCC patients should be actively pursued.

Clinical Trial Description

n/a

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01472419
Study type Observational
Source Samsung Medical Center
Contact
Status Completed
Phase N/A
Start date March 2012
Completion date March 2013
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01142388 - Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06138028 - Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer Phase 2/Phase 3
Recruiting NCT05512520 - Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003） Phase 2
Active, not recruiting NCT05142709 - Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Completed NCT06190652 - Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
Not yet recruiting NCT05522894 - AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC Phase 2
Enrolling by invitation NCT03800953 - The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT06265285 - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Phase 2
Recruiting NCT04949256 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) Phase 3
Recruiting NCT05978193 - Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05760391 - A Study of IO Plus Radiotherapy in Patients With Advanced ESCC. N/A
Active, not recruiting NCT04460937 - Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Phase 1